Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Mission Bio Develops Single-Cell Solution to Address Challenges in Genome Editing
Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, […]
Gene & Cell Therapy Manufacturing Specialist Ascend Launches With Over $130M of Funding
Ascend Gene & Cell Therapies (Ascend), a specialist company innovating manufacturing processes to improve quality, […]
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases […]
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, a clinical stage genome editing company, today announced that the US Food and […]
AmerisourceBergen Launches Cell and Gene Therapy Innovation Hub
AmerisourceBergen, a global healthcare company, has announced the launch of its Cell and Gene Therapy […]
Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs
Forge Biologics, a leading manufacturer of genetic medicines, today announced that its manufacturing facility has […]
TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research for DMD
Precision BioSciences, a clinical-stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and […]
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Gamida Cell, a cell therapy pioneer working to turn cells into powerful therapeutics, today announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more